1-for-25 reverse split takes effect for Ernexa Therapeutics (NASDAQ: ERNA)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Ernexa Therapeutics Inc. approved a structural change to its capital by filing a Certificate of Amendment in Delaware to implement a 1-for-25 reverse stock split of its common stock. This consolidates every 25 existing shares into 1 share.
The reverse split became effective for trading on Nasdaq at market open on May 4, 2026, when the common stock began trading on a split-adjusted basis under the existing ERNA symbol. The company’s common stock now carries a new CUSIP number, 114082407, following the reverse stock split.
Positive
- None.
Negative
- None.
Insights
Ernexa consolidates its share count with a 1-for-25 reverse split.
Ernexa Therapeutics implemented a 1-for-25 reverse stock split through a Certificate of Amendment to its Restated Certificate of Incorporation. This action reduces the number of outstanding common shares while proportionally increasing the price per share, leaving overall market capitalization broadly unchanged at implementation.
The reverse split became effective for Nasdaq trading at market open on May 4, 2026, and the common stock now trades on a split-adjusted basis with new CUSIP 114082407. The filing focuses on the legal mechanics of the split and does not discuss broader strategic goals or financial impacts.
8-K Event Classification
2 items: 5.03, 9.01
2 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Reverse split ratio: 1-for-25
Effective trading date: May 4, 2026
Par value per share: $0.005 per share
+1 more
4 metrics
Reverse split ratio
1-for-25
Reverse stock split of common stock
Effective trading date
May 4, 2026
Date shares began trading on split-adjusted basis on Nasdaq
Par value per share
$0.005 per share
Par value of common stock listed in securities table
New CUSIP
114082407
CUSIP for common stock after reverse split
Key Terms
reverse stock split, Certificate of Amendment, Restated Certificate of Incorporation, Nasdaq, +1 more
5 terms
reverse stock split financial
"to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-25"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Certificate of Amendment regulatory
"filed a certificate of amendment (the “Certificate of Amendment”) to the Company’s Restated Certificate of Incorporation"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
Restated Certificate of Incorporation regulatory
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation, filed May 1, 2026"
A restated certificate of incorporation is an updated, single-document version of a company’s founding rules that folds together the original charter and all later changes into one clear set of terms — like replacing a patchwork manual with a clean, revised edition. Investors care because it clarifies ownership details, voting rights, share classes and other legal rules that affect control, dividends and how value is created or diluted, so it can change the risks and benefits of owning the stock.
Nasdaq financial
"the common stock began trading on a split-adjusted basis on Nasdaq"
The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.
CUSIP number financial
"The new CUSIP number for the common stock following the Reverse Stock Split is 114082407."
A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.
FAQ
What reverse stock split did Ernexa Therapeutics (ERNA) implement?
Ernexa Therapeutics implemented a 1-for-25 reverse stock split of its common stock. Every 25 pre-split shares were consolidated into 1 post-split share, changing share count and per-share price but not the overall value at the moment of the split.
When did Ernexa Therapeutics’ 1-for-25 reverse split become effective?
The reverse stock split became effective for trading at market open on May 4, 2026. From that date, Ernexa Therapeutics’ common stock has traded on Nasdaq on a split-adjusted basis under the existing ERNA symbol, reflecting the new share structure.
What legal step did Ernexa Therapeutics (ERNA) take to effect the reverse split?
Ernexa Therapeutics filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Delaware Secretary of State. This amendment formally authorized the 1-for-25 reverse stock split of its common stock as described in the Form 8-K filing.
Did Ernexa Therapeutics’ Nasdaq ticker change after the reverse split?
The Nasdaq ticker symbols remained the same after the reverse split, with common stock continuing under ERNA. However, the common stock received a new CUSIP number, 114082407, once trading began on a split-adjusted basis following the 1-for-25 consolidation.
What new CUSIP number applies to Ernexa Therapeutics’ common stock after the split?
After the 1-for-25 reverse stock split, Ernexa Therapeutics’ common stock began using CUSIP number 114082407. This new identifier corresponds to the post-split shares that started trading on a split-adjusted basis on Nasdaq beginning May 4, 2026.